Nuclear Magnetic Resonance Spectroscopic Analysis of Urinary Metabolome in

Status Completed

Clinical Trial Summary

"Sarcoidosis is a systemic granulomatous disease of unknown cause(s).Determining disease activity is a major element in the treatment decision. 1H- Nuclear magnetic resonance (NMR) spectroscopy allows the identification of biomarkers in different pathologies and in particular in a pilot study of saliva of patients with sarcoidosis. Applications to sarcoidosis are still rare, having concerned only serum and saliva. In this context we hypothesize the existence of a difference in the metabolic products found in the urine of sarcoidosis patients with different degrees of activity and/or disease severity. We designed an analysis of urinary metabolomics in sarcoidosis patient using NMR spectroscopy with multivariate statistical analysis, followed by metabolite identification and pathway analysis. "

Clinical Trial Description

"Sarcoidosis is a systemic granulomatous disease of unknown cause(s) with an almost constant lung involvement. Clinical expression varies greatly in both evolution and severity. The activity of the disease is currently based on serum markers (elevation of angiotensin-converting enzyme) with poor sensitivity/specificity or on imaging techniques (18F-FDG PET-CT) which are more invasive and more expensive. Determining disease activity is a major element in the treatment decision. The spectra of small molecules resulting from metabolism (metabolome/metabolomics) evaluated by spectrometry in different biological fluids (blood, saliva, urine) during different physiological or pathological conditions have been identified as promising biomarkers. 1H- Nuclear magnetic resonance (NMR) spectrometry allows the identification of biomarkers in different pathologies and in particular in a pilot study of saliva of patients with sarcoidosis. Applications to sarcoidosis are still rare having concerned only serum and saliva. The application of this method to the urinary metabolome has shown its effectiveness in other situations, for example in celiac disease. In this context we hypothesize the existence of a difference in the metabolic products found in the urine of sarcoidosis patients with different degrees of activity and/or disease severity. We designed an analysis of urinary metabolomics in sarcoidosis patient using NMR spectroscopy with multivariate statistical analysis, followed by metabolite identification and pathway analysis. " ;

Study Design

Related Conditions & MeSH terms

Sarcoidosis

Clinical Trial Details

NCT number	NCT05181930
Study type	Observational
Source	Assistance Publique - Hôpitaux de Paris
Contact
Status	Completed
Phase
Start date	January 30, 2018
Completion date	June 1, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04008069` - Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis	Phase 2
Recruiting	`NCT02807025` - Nasal, Tracheal and Bronchial Mucosal Lining Fluid(MLF) Sampling From Patients With Respiratory Diseases	N/A
Completed	`NCT01615484` - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability	N/A
Completed	`NCT00274352` - A Study of Adalimumab to Treat Sarcoidosis of the Skin	Phase 2
Completed	`NCT00373555` - Endobronchial Ultrasonography in the Diagnosis of Sarcoidosis	N/A
Completed	`NCT00326534` - Rickettsial Genesis to Sarcoidosis in Denmark	N/A
Recruiting	`NCT00470327` - A Study of the Natural Progression of Interstitial Lung Disease (ILD)
Completed	`NCT00512967` - The Occurence of Inflammation and Oxidative Stress in Lung Diseases	N/A
Recruiting	`NCT01745237` - Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis
Completed	`NCT00369980` - Diagnostic Usefulness of Fluorine–18-α–Methyltyrosine PET in Combination With 18F-FDG in Sarcoidosis Patient	N/A
Completed	`NCT00379275` - Eye and Immunogenetic Features of Sarcoidosis	N/A
Completed	`NCT00366509` - Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
Completed	`NCT06396910` - TB and Sarcoidosis Granuloma
Completed	`NCT04156789` - Obstructive Sleep Apnoea in Sarcoidosis
Recruiting	`NCT02916459` - EBUS-TBNA vs Flex 19G EBUS-TBNA	N/A
Recruiting	`NCT02827734` - Evaluation of Novel Lung Function Parameters in Patients With Interstitial Lung Disease (ILD)
Completed	`NCT02546388` - Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis	N/A
Completed	`NCT01687517` - Efficacy and Safety of Influenza Vaccine During Sarcoidosis	Phase 3
Completed	`NCT01139710` - Sarcoidosis-associated Pulmonary Hypertension	N/A
Terminated	`NCT00747461` - Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD")	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Nuclear Magnetic Resonance Spectroscopic Analysis of Urinary Metabolome in Sarcoidosis (RMN-SARCURINES) — RMN-SARCURINES

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms